logo
Laurus Labs Ltd.
05 Dec 2016
861.20
1.40%
Ashika Research
The company operates in 4 segments: Generics APIs, Generics FDFs, Synthesis and Ingredients. Generics API business comprises the development, manufacture and sale of APIs and advanced intermediates; Generics FDF business comprises the development and manufacture of oral solid formulations; Synthesis business includes contract development and manufacturing services for global pharmaceutical companies; and Ingredients business comprises the manufacture and sale of specialty ingredients for use in the nutraceutical and cosmeceutical sectors....
Laurus Labs Ltd. has an average target of 686.25 from 4 brokers.
More from Laurus Labs Ltd.
Recommended